Table 1.
Baseline data of the included 118 patients
| Variables | Group | n (%) |
|---|---|---|
| Sex | ||
| Male | 63 | 53.39 |
| Female | 55 | 46.61 |
| Age (years) | ||
| > 60 | 69 | 58.47 |
| ≤ 60 | 49 | 41.53 |
| Differentiation extent | ||
| Moderate/high differentiation | 32 | 27.12 |
| Poor differentiation | 86 | 72.88 |
| Tumor location | ||
| Head of pancreas | 71 | 60.17 |
| Pancreatic body and tail | 47 | 39.83 |
| Tumor invasion of large blood vessels | ||
| Yes | 58 | 49.15 |
| No | 60 | 50.85 |
| Distant metastasis | ||
| Yes | 46 | 41.53 |
| No | 72 | 61.01 |
| Chemotherapy regimen | ||
| FOLFIRINOX | 46 | 38.98 |
| AG | 39 | 33.05 |
| GS | 19 | 16.10 |
| AS | 14 | 11.86 |
Note: AG, gemcitabine + albumin-bound paclitaxel; GS, gemcitabine + Teggio; AS, albumin-bound + Teggio; FAR, fibrinogen/albumin ratio; NLR, neutrophil/lymphocyte ratio.